相关实验视频

Updated: May 25, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

我们如何治疗复发性耐火妊娠性热囊细胞瘤 - 一个令人兴奋的案例系列

Kritthivasan Venkatakrishnan¹, Jayachandran Perumal Kalaiyarasi¹, Jayashree Natarajan²

¹Department of Medical Oncology, Cancer Institute (W.I.A), Chennai, India.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

|February 27, 2025

概括

复发性/不耐药的妊娠热囊细胞瘤 (RR-GTN) 是一个具有挑战性的治疗. 这项研究探讨了RR-GTN的手术,免疫疗法 (pembrolizumab) 和干细胞移植,为患者提供了新的希望.

科学领域:

妇科瘤学妇科瘤学
医学瘤学医学瘤学
血液学血液学血液学

背景情况:

复发性/耐药性妊娠热囊细胞瘤 (RR-GTN) 是一个重大的临床挑战.
对于那些未能接受一线治疗的患者,治疗选择有限.

研究的目的:

描述RR-GTN的独特情况.
审查RR-GTN的可用的治疗选择.

主要方法:

三名RR-GTN患者的病例系列在2021年1月至2022年12月期间接受治疗.
患者已经失败了两个或两个以上的标准治疗线.
收集的数据包括临床特征,治疗方案,毒性和结果.

主要成果:

使用了三种不同的治疗方法:手术,布罗利祖马布免疫疗法和协同自主干细胞移植.
为RR-GTN提供了文献综述和管理指南.

结论:

强化化疗,免疫检查点抑制剂和自身干细胞移植对高风险的RR-GTN有希望.
需要进行临床试验来确定最佳的治疗序列,尽管由于稀有性而具有挑战性.

关键词:

在GTN中进行自身干细胞移植.在GTN中高剂量化疗.在GTN中使用 pembrolizumab.复发/耐药的妊娠 trofhoblastic 瘤.用PD-1抑制剂恢复化学敏感性

更多相关视频

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...